HIV/AIDS Workshop

Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) is clinical research collaboration on infectious diseases between the National Institute of Health Research and Development (NIHRD), Ministry of Health of Indonesia and the U.S. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). We establish a network of infectious diseases research and build capacity and infrastructure to conduct high quality clinical research in Indonesia. Established in 2011, we have completed a study to determine the etiology of acute fever in hospitalized patients (the Etiology of Acute Febrile Illnesses Requiring Hospitalization / AFIRE Study). Our ongoing studies include a 2-year cohort on drug resistant tuberculosis (Tuberculosis Research on Drug Resistance / TRIPOD Study) and a 3-year cohort on HIV infection (Prospective Observational Cohort on HIV Infection and Risk-Related Coinfections/ Comorbidities in Indonesia / INA-PROACTIVE).

With regards to the vision of Three Zeros (zero AIDS-related deaths, zero new HIV infections, and zero HIV/AIDS stigma and discrimination), the HIV/AIDS epidemic in Indonesia is unfortunately still increasing, as opposed to other neighbouring countries such as India and Thailand. The estimated HIV prevalence rate in Indonesian adults aged 15-49 years rose from 0.3% in 2011 to 0.5% in 2015. Indonesia, India, and China account for 78% of new HIV infections in Asia Pacific region in 2014. In 2016, there was an estimated 622,435 people living with HIV (PLWH) in Indonesia; 248,250 of the PLWH knew their HIV statuses and 79,833 of them were on treatment. The HIV transmission pattern had moved from injecting drug use (53% in 2001-2005 to 34% in 2011) to heterosexual transmission (37% to 71% during that same period).

The INA-PROACTIVE study aimed to fill the gap on viral suppression among PLWH in Indonesia. In addition, we want to capture HIV disease progression and outcomes, as well as its association with various demographical and clinical factors. Between January and September 2018, INA-PROACTIVE study has enrolled over 850 participants from 12 sites in Indonesia. The 12 sites are either type A or B or private hospital capable of delivering HIV care, which include Dr. Cipto Mangunkusumo Hospital, Persahabatan Hospital, and St. Carolus Hospital in Jakarta; Dr. Kariadi Hospital, Semarang; Dr. Sardjito Hospital, Yogyakarta; Dr. Soetomo Hospital, Surabaya; Dr. Wahidin Sudirohusodo Hospital, Makassar; Kab. Tangerang Hospital, Banten; Dr. Adam Malik Hospital, Medan; Budi Kemuliaan Batam Hospital; Dr. Ansari Saleh Hospital, Banjarmasin; and Dr. A. W. Sjahranie, Samarinda. Although the study site team has been given training prior to site activation, it is deemed necessary to refresh their knowledge in managing HIV patients, from making diagnoses and providing treatment of HIV infection and its coinfections/comorbidities, as well as addressing social implications of PLWH.


The purpose of the INA-RESPOND HIV seminar is to:

  1. Refresh knowledge on HIV basics, such as epidemiology, retrovirology, diagnostics and antiretroviral treatment guideline.
  2. Refresh knowledge on the management of HIV coinfections and comorbidities, such as opportunistic infections, metabolic diseases, cancer, etc.
  3. Refresh knowledge on the management of pediatric HIV.
  4. Discuss difficult and interesting cases found in HIV clinic.
  5. Provide latest update on HIV prevention and challenges.


Agenda and other details can be seen from the leaflet link: HIV Seminar at Double Tree Hotel Jakarta

Looking forward to seeing you in the seminar!

Leave a reply